Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173


Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.

Verschoor AJ, Speetjens FM, Dijkstra PDS, Fiocco M, van de Sande MAJ, Bovée JVMG, Gelderblom H.

Oncologist. 2019 Dec 19. pii: theoncologist.2019-0528. doi: 10.1634/theoncologist.2019-0528. [Epub ahead of print]


A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival.

de Jong Y, Bennani F, van Oosterwijk JG, Alberti G, Baranski Z, Wijers-Koster P, Venneker S, Briaire-de Bruij IH, van de Akker BE, Baelde H, Cleton-Jansen AM, van de Water B, Danen EHJ, Bovée JVMG.

J Bone Oncol. 2019 Nov 17;19:100268. doi: 10.1016/j.jbo.2019.100268. eCollection 2019 Dec.


Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker S, Kruisselbrink AB, Briaire-de Bruijn IH, de Jong Y, van Wijnen AJ, Danen EHJ, Bovée JVMG.

Cancers (Basel). 2019 Dec 2;11(12). pii: E1918. doi: 10.3390/cancers11121918.


Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma.

Lam SW, Cleven AHG, Kroon HM, Briaire-de Bruijn IH, Szuhai K, Bovée JVMG.

Virchows Arch. 2019 Nov 25. doi: 10.1007/s00428-019-02684-9. [Epub ahead of print]


What's new in bone forming tumours of the skeleton?

Franceschini N, Lam SW, Cleton-Jansen AM, Bovée JVMG.

Virchows Arch. 2020 Jan;476(1):147-157. doi: 10.1007/s00428-019-02683-w. Epub 2019 Nov 18. Review.


Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.

Venneker S, Szuhai K, Hogendoorn PCW, Bovée JVMG.

Virchows Arch. 2020 Jan;476(1):135-146. doi: 10.1007/s00428-019-02699-2. Epub 2019 Nov 14. Review.


A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation.

Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, Salas S, Bonhomme B, Gomez-Brouchet A, Laurent C, Le Guellec S, Audard V, Giraud A, Ramos-Oliver I, Cleton-Jansen AM, Savci-Heijink DC, Kroon HM, Baud J, Pissaloux D, Pierron G, Sherwood A, Coindre JM, Bovée JVMG, Larousserie F, Tirode F.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0323-8. [Epub ahead of print]


Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.

Lam SW, van Langevelde K, Suurmeijer AJH, Cleven AHG, Bovée JVMG.

Histopathology. 2019 Dec;75(6):843-852. doi: 10.1111/his.13952. Epub 2019 Sep 13.


NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.

Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z.

Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.


Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.

de Jong Y, Ingola M, Briaire-de Bruijn IH, Kruisselbrink AB, Venneker S, Palubeckaite I, Heijs BPAM, Cleton-Jansen AM, Haas RLM, Bovée JVMG.

Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.


Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas.

van IJzendoorn DGP, Szuhai K, Briaire-de Bruijn IH, Kostine M, Kuijjer ML, Bovée JVMG.

PLoS Comput Biol. 2019 Feb 20;15(2):e1006826. doi: 10.1371/journal.pcbi.1006826. eCollection 2019 Feb.


Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.

Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG.

J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr.


Prevalence and Clinical Features of Mazabraud Syndrome: A Multicenter European Study.

Majoor BCJ, van de Sande MAJ, Appelman-Dijkstra NM, Leithner A, Jutte PC, Vélez R, Perlaky T, Staals EL, Bovée JVMG, Hamdy NAT, Dijkstra SPD.

J Bone Joint Surg Am. 2019 Jan 16;101(2):160-168. doi: 10.2106/JBJS.18.00062.


Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production.

van den Bosch MHJ, Ramos YFM, den Hollander W, Bomer N, Nelissen RGHH, Bovée JVMG, van den Berg WB, van Lent PLEM, Blom AB, van der Kraan PM, Meulenbelt I.

Rheumatology (Oxford). 2019 Jun 1;58(6):1065-1074. doi: 10.1093/rheumatology/key426.


Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature.

Song W, Suurmeijer AJH, Bollen SM, Cleton-Jansen AM, Bovée JVMG, Kroon HM.

Skeletal Radiol. 2019 Jul;48(7):1059-1067. doi: 10.1007/s00256-018-3135-x. Epub 2019 Jan 2. Review.


Molecular Pathology of Bone Tumors.

Lam SW, van IJzendoorn DGP, Cleton-Jansen AM, Szuhai K, Bovée JVMG.

J Mol Diagn. 2019 Mar;21(2):171-182. doi: 10.1016/j.jmoldx.2018.11.002. Epub 2018 Dec 18. Review.


Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.

de Jong Y, Monderer D, Brandinelli E, Monchanin M, van den Akker BE, van Oosterwijk JG, Blay JY, Dutour A, Bovée JVMG.

Oncogenesis. 2018 Sep 21;7(9):74. doi: 10.1038/s41389-018-0084-0.


Jason L. Hornick: Practical soft tissue pathology: a diagnostic approach, 2nd edition.

Bovée JVMG.

Virchows Arch. 2018 Dec;473(6):785-786. doi: 10.1007/s00428-018-2440-z. Epub 2018 Aug 29. No abstract available.


Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis.

Song W, van den Berg E, Kwee TC, Jutte PC, Cleton-Jansen AM, Bovée JVMG, Suurmeijer AJ.

Clin Sarcoma Res. 2018 Aug 23;8:16. doi: 10.1186/s13569-018-0104-z. eCollection 2018.


Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?

Mastboom MJL, Hoek DM, Bovée JVMG, van de Sande MAJ, Szuhai K.

Histopathology. 2019 Jan;74(2):332-340. doi: 10.1111/his.13744. Epub 2018 Nov 11.


Supplemental Content

Loading ...
Support Center